JAK2 (V617F) mutation is not associated with thrombosis in Behcet syndrome.

Abstract

The Janus kinase 2(V617F) (JAK2 (V617F)) mutation is an acquired genetic defect that is considered to enhance thrombosis in Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs). Thrombosis is also a well-defined component of Behcet syndrome (BS). The aim of this study was to determine the frequency of JAK2 ( V617F ) mutation in BS-associated thrombosis. A total of 152 patients with BS (62 with thrombosis and 90 without thrombosis) were enrolled. An additional 186 patients with MPNs and 107 healthy blood donors were included to serve as diseased and healthy controls, respectively. None of the patients with BS and healthy controls carried the JAK2 (V617F) mutation, whereas 67% of patients with MPNs were positive for JAK2 ( V617F ). The frequency of thrombosis in patients with MPNs was not statistically different between carriers and non-carriers of JAK2 ( V617F ) mutation. Our data suggest that JAK2 (V617F) is not directly related to thrombosis in MPNs and in other thrombotic entities, such as BS.

DOI: 10.1177/1076029611427440

Statistics

020040020132014201520162017
Citations per Year

151 Citations

Semantic Scholar estimates that this publication has 151 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Ar2012JAK2M, title={JAK2 (V617F) mutation is not associated with thrombosis in Behcet syndrome.}, author={Muhlis Cem Ar and G{\"{u}len Hatemi and Seda Ekizoğlu and H{\"{u}lya Selva Bilgen and Sevgi Saçli and Ayse Nur Buyru and Teoman Soysal and Birsen {\"{U}lk{\"{u} and Hasan Yazici}, journal={Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis}, year={2012}, volume={18 4}, pages={421-6} }